The presence of regulatory T cells (Tregs) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag SNPs in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) ] after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs appear to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid EOC.
Abstract
The presence of regulatory T cells (Tregs) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag SNPs in 25 Treg-associated genes (CD28, CTLA4,   FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including ] after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs appear to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid EOC.
Introduction
There were an estimated 15,500 deaths from ovarian cancer in the United States in 2012 (1) in part because many tumors are diagnosed at late stage and recurrences are common. Invasive epithelial ovarian cancer (EOC) consists of several histological subtypes with varying behavior and survival (2), and the rare subtypes are often understudied because of limited numbers. Nonetheless, subtype-specific analysis of EOC is needed to better understand prognostic factors. By combining cases across many studies in the Ovarian Cancer Association Consortium (OCAC), these subtype analyses may now be conducted.
Antitumor immunity by cytotoxic T cells has been demonstrated in ovarian cancer
(1) and recent meta-analyses concluded that tumor-infiltrating immune cells predict improved survival in EOC (2) and other malignancies (3). However, in the tumor microenvironment, the function of these cells is often suppressed by a mixture of suppressive cytokines produced by the tumor and by the different populations of suppressive immune cells (4) . Of particular interest are regulatory T cells (Tregs), which develop in the thymus (natural) or periphery (acquired) and typically express CD4 and FOXP3 (5) . These cells interact with antigen presenting cells (APCs) via cell surface molecules, such as CTLA4, to inhibit antigen presentation and to induce APCs to express suppressive cytokines (6) . Their presence in tumors has been linked to poor prognosis in EOC patients (7) .
Based on this knowledge, we hypothesized that genetic variants in genes activated in suppressive immune cells may associate with EOC survival. Previously, Table 1 ). The relevance of these genes was established from a PubMed database search which revealed published information that either directly showed or suggested a role for the respective gene products in the induction, immune suppressive function, or trafficking of Tregs (8) . We selected 749
SNPs in these genes, including 5 kb upstream and downstream, in attempt to tag all common variants using the criteria that all known SNPs with MAF ≥ 0.05 had an r 2 ≥ 0.8 with at least one tag SNP in the region. Additional SNP information is presented in Supplemental Table 2 .
Study Participants, Genotyping, and Quality Control. A total of 10,084 invasive EOC cases, of which 5,248 were high-grade serous cases, were examined. Germline DNA (250 ng genomic or 750 ng whole-genome amplified) from participants from 28 studies (Supplemental Table 3 ) in the OCAC was genotyped on a custom Illumina iSelect BeadArray, using centralized genotype calling and quality control (QC) procedures, as described previously (9-13). In brief, we excluded samples with call rate < 95% and SNPs with call rate < 95% (MAF ≥ 0.05) or < 99% (MAF < 0.05); we (14) . PolyDoms predicts the implications of the non-synonymous SNPs (nsSNPs) using Table 4 ). Two different Cox models were created to adjust for relevant covariates: a minimally adjusted Cox model adjusted for age at diagnosis, the first five population substructure PCs, and study site; and a Cox model endometrioid, 5 clear cell, 5 mucinous) with matching gene expression and genotype data for rs11256497 and analyzed as described previously (8) . Briefly, data were normalized via the Agilent error model and log ratios of signal relative to a reference were used for analyses. After normalization, batch differences caused by Cy5 (case channel) and Cy3 (reference channel) dying dates were adjusted using ComBat, an empirical Bayesian approach (17 Treg-related genes for associations with overall survival (OS). The median survival time across the 28 studies included in this analysis ranged from 2.2-8.6 years (Supplemental Table 3 ). combined histolog. However, when we restricted the analysis to endometrioid histology, IL2RA expression was lower in the AG/AA group, compared to the GG group (p=0.001 for probe A_23_P237288 and p=0.01 for probe A_24_P230563; Figure 3 ).
Associations between Treg SNPs and survival among all cases with EOC and by specific tumor histologies
Lastly, using in silico tools, we determined whether there was information regarding the role of the SNPs in regulating the function and/or expression of the genes with which they are associated. First, we accessed RegulomeDB to determine if any of the intronic SNPs with a p < 0.001 (Table 1 bolded) may be associated with regions involved in the regulation of expression. This included all of the identified SNPs with the exception of rs231775, a coding SNP. The only SNP that was in a region for which binding of regulatory elements was considered likely was rs11256497 within the IL2RA gene, which is in agreement with the expression results depicted in Figure 3 . While dbSNP did not provide additional information with respect to this SNP, using this tool we found two other IL2RA SNPs, rs10905669 and rs10795763, within 2.5 kb of the promoter regions suggesting a role for these SNPs in regulating expression. The only SNP relevant to the PolyDom algorithm (i.e., within a coding region) was the CTLA4 missense SNP rs231775 which was predicted to be a benign variant. 
Discussion
Infiltration of ovarian tumors by Tregs is associated with poor patient outcome (7) . Previously, we found associations between overall survival in EOC and SNPs in genes related to Treg activation, migration, and function, including RGS1 (clear cell), LRRC32 and TNFRSF18/TNFRSF4 (mucinous), and CD80 (endometrioid) (8) . In the present study, we assessed the associations between overall survival in EOC patients and germline variations in additional Treg-related genes. The most notable associations (p<6.2x10 -4 ) were found between six SNPs in IL2RA and OS in women with endometrioid cancer, a CTLA4 SNP and OS in women with clear cell carcinoma, a TGFBR2 SNP and OS in women with high-grade serous EOC, and a TFGBR2 SNP and OS in women with any EOC. There were also a few modest associations between OS and Treg-related SNPs in TGFBR2 and IL10RA for all EOC, TGFBR2 for high-grade serous, TGFBR2 for endometrioid, MAP3K8 for clear cell, and TGFBR2 and TGFBR3 for patients with mucinous EOC.
The most statistically significant association found was between overall survival in women with endometrioid EOC and IL2RA SNP, rs11256497. IL-2Rα, also known as CD25, forms a portion of the high affinity IL-2 receptor, is expressed by most Tregs. IL-2 signaling through this receptor plays an important role in Treg homeostasis (18) . IL-2 treatment has been shown to enhance Treg numbers and function (19) , while anti-CD25 antibodies can be used to deplete Tregs (20) . The rs11256497 SNP, associated with OS in our study, is located in an NF-κB and EBF1 binding site (HaploReg v2) (described with matching tumor mRNA expression and rs11256497 genotype data revealed elevated IL2RA mRNA expression in the tumors of patients with the GG genotype, which was also associated with improved survival, compared to patients with the AA/AG genotype. This finding seems counterintuitive, as higher IL2RA would be predicted to associate with higher Treg counts and therefore reduced survival; however, prior studies have identified the complexity of IL-2/IL-2Rα signaling and its importance in effector T cell response (21) . We also note that sample size was limited for endometrioid cases with overlapping genotype and gene expression data. These data also do not permit an evaluation of whether or not these SNPs alter expression in success in inducing tumor regression of melanoma and renal clear cell carcinoma (26) .
Recent studies in rodent models have demonstrated that treatment with anti-CTLA4
antibodies results in enhanced tumor rejection and higher intratumoral ratio of effector T cell/Treg (27, 28) . While further experimental studies should be carried out to evaluate how this genetic association translates into clinical application, our findings combined with that in the previous reports of clear cell EOC being molecularly similar to renal clear cell carcinoma (29) , indicate that blocking CTLA4 with an agent such as ipilimumab might be reasonable to investigate in clinical trials for clear cell EOC. A phase II study of this drug currently is underway in recurrent platinum-sensitive ovarian cancer (www.clinicaltrials.gov).
The strengths of this study include centralized QC and large sample size, thus providing the opportunity to examine associations between survival and SNPs with more modest effects in patients with the common high-grade serous histology and those with the rare histologic subtypes. Our study include samples from 28 EOC studies with different designs and goals, and we controlled for potentially confounding factors by adjusting for study site and several clinical covariates for which information was available in a large portion of the OCAC population. While we were limited by the number of cases with non-missing debulking status and therefore did not perform this adjustment in our primary analysis, we did perform sensitivity analyses in cases with non-missing debulking status. We used a fairly comprehensive approach (SNPtagging) to identify variations in Treg-related genes; however, due to QC failures, some genes were not as well-covered as others. Differences in enrollment time, particularly for population-based studies with delayed enrollment, may also affect the results due to 
a failure to enroll subjects, who died very soon after diagnosis. While adjustment for left truncation removes some of the biases, an increased survival time was still evident.
Finally, due to variation in racial differences in allele frequencies and the limited number of racial minorities, the analysis was restricted to participants of European descent, which reduces generalizability.
In conclusion, we provide evidence that Treg-related SNPs are associated with survival in subtypes of EOC. In particular, several SNPs in IL2RA are associated with survival in endometrioid EOC. We found that the minor allele of a missense CTLA4 SNP, previously reported to be associated with impaired CTLA4 function and several 
